#USA #Wilmington #Single-Cell #DeepCyte #AI toxicology

DeepCyte Secures $1.5 Million for Single-Cell AI Toxicology

DeepCyte, a biotechnology startup, has successfully raised $1.5 million in seed funding aimed at revolutionizing drug development through innovative AI toxicology solutions. The company, which operates from both Wilmington, Delaware, and Copenhagen, Denmark, is set to introduce two groundbreaking technologies that enhance the detection and prediction of drug toxicity at the single-cell level.

Drug toxicity remains a significant challenge in the pharmaceutical industry, responsible for a high rate of clinical trial failures and drug withdrawals. Traditional testing methods, which rely heavily on animal models and bulk assays, often fall short in accurately predicting human responses. Furthermore, they tend to overlook the complex cellular variations that contribute to adverse drug reactions. This gap in efficacy has led to an increasing demand for more precise and predictive toxicology solutions that align with the regulatory shift towards human-relevant testing methodologies.

DeepCyte's Innovative Approach

At the forefront of this initiative is DeepCyte's MetaCore, a high-throughput metabolomics platform that utilizes laser-based sampling and mass spectrometry technologies. MetaCore stands out by providing comprehensive molecular profiles of cellular responses, thus capturing the intricacies that bulk assays often fail to address. This innovative platform facilitates the generation of vast, AI-ready data sets while minimizing sample preparation efforts and costs.

Alongside MetaCore, the company is rolling out DeeImmuno, its first AI solution designed to work with MetaCore's data. Trained on specialized single-cell metabolomics atlases, DeeImmuno leverages machine learning to predict toxicity classifications, identify crucial biomarkers, and infer the underlying mechanisms of toxicity. In evaluations involving 100 drugs that had been set aside, DeeImmuno achieved an impressive 94% accuracy in predicting 17 distinct toxicity mechanisms—setting a new standard for mechanistic resolution that has not been achievable through conventional methodologies.

Leadership and Future Directions

DeepCyte is helmed by CEO Theodore Alexandrov, a distinguished leader with a strong background in pharmacology and artificial intelligence. Previously, Alexandrov was instrumental in developing METASPACE, a cloud-based software that has been embraced by thousands of researchers around the world. He also co-founded SCiLS GmbH, which was later acquired by Bruker. Under his guidance, DeepCyte aims not only to develop effective toxicity prediction tools but to fundamentally transform how safety testing is conducted in preclinical stages.

The recent funding round has attracted notable backing from Carl J. G. Evertsz, a medtech executive and former CEO who will now take on the role of Board Chair. This support underscores confidence in DeepCyte's groundbreaking approach and its vision of achieving human-centric drug safety testing.

A Commitment to Changing Toxicology

DeepCyte's mission is clear: to uncover and mitigate toxicity risks at the cellular level before drugs are ever administered to patients. By utilizing the latest advancements in AI and single-cell biology, they aim to redefine the standards for drug safety research. As the pharmaceutical landscape continues to evolve, DeepCyte's innovative technologies could play a pivotal role in enhancing the predictability of drug toxicity and ultimately improving patient safety in drug therapies.

As the industry eagerly watches the development of these technologies, one thing remains sure: the future of drug testing is undoubtedly heading toward a more human-centric approach.